RespireRx Pharmaceuticals Inc (RSPI)

[Investor2014]

Nail in the coffin?

“Sleep apnea biotech breathes easy with $62.5M financing ahead of PhIII trials for lead oral drug
Lei Lei Wu
News Reporter
Traditional care for obstructive sleep apnea involves CPAP, a cumbersome countermeasure in which patients have air continuously pushed through a mask they have to wear through the night. While there have been improvements to CPAP technology, it has remained the standard of care for obstructive sleep apnea since its invention just over 40 years ago.

However, Cambridge-based biotech Apnimed is now touting that it may have an oral drug that could change that standard, and it has won $62.5 million in Series C funding to fuel an upcoming Phase III trial for said candidate to test that claim.

The biotech initially set out to raise $50 million, but overshot their goal. “That’s always a good sign,” CEO Lawrence Miller said to Endpoints News.”

https://endpts.com/sleep-apnea-biotech-breathes-easy-with-62-5m-financing-ahead-of-phiii-trials-for-lead-oral-drug/